Answers are grounded in this paper and cite their sources.
This study investigated the antidiabetic and immunometabolic potential of microencapsulated Lacticaseibacillus casei and Lactobacillus acidophilus —isolated from traditional Iranian cheeses—in an HFD/STZ-induced type 2 diabetes mellitus (T2DM) rat model. Following the selection of two strains based on robust in vitro probiotic attributes, including acid/bile tolerance (>60%), cell-surface hydrophobicity (>63%), and antimicrobial efficacy (inhibition zones ≥21 mm), the microencapsulated probiotics were administered at a dosage of 1 × 10 9 CFU/mL/day for 6 weeks. The intervention significantly ameliorated the diabetic phenotype; probiotic supplementation decreased serum leptin levels (from 13.79 to 11.06 ng/mL) and elevated adiponectin concentrations (from 0.33 to 0.49 ng/mL). Additionally, treated animals exhibited a significantly improved lipid profile—marked by reductions in total cholesterol, triglycerides, and LDL-C, alongside increased HDL-C—and better maintenance of body weight compared with untreated diabetic controls. Molecular analyses, including qRT-PCR and ELISA, revealed that probiotic administration upregulated key metabolic regulators, including Adipoq, AMPK, GLUT4, PPAR-γ, and AdipoR1, while downregulating inflammatory and lipogenic mediators such as NF-κB, IL-6, TNF-α, SREBP-1c, and leptin. These findings demonstrate that microencapsulated L. casei and L. acidophilus exert beneficial immunometabolic effects in diabetic rats, positioning them as promising functional food candidates for T2DM management. Controlled clinical trials are now warranted to evaluate these therapeutic outcomes in human subjects.
No takes yet. Share an insight, caveat, or question.
Nami et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: